Identification of a 6-Cytokine Prognostic Signature in Patients with Primary Glioblastoma Harboring M2 Microglia/Macrophage Phenotype Relevance

Jinquan Cai1,5*, Wei Zhang2,4,5*, Pei Yang2,4,5*, Yinyan Wang2,4,5*, Mingyang Li2,4,5*, Chuanbao Zhang2,4,5, Zheng Wang2,4,5, Huimin Hu2,5, Yanwei Liu2,4,5, Qingbin Li1,5, Jinchong Wen1,5, Bo Sun1,5, Xiaofeng Wang1,5, Tao Jiang2,3,4,5, Chuanlu Jiang1,5, * These authors contributed equally to this work.

1 Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China, 2 Beijing Neurosurgical Institute, Capital Medical University, Beijing, China, 3 Beijing Institute for Brain Disorders Brain Tumor Center, Beijing, China, 4 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, 5 Chinese Glioma Cooperative Group (CGCG), Beijing, China

OPEN ACCESS

Citation: Cai J, Zhang W, Yang P, Wang Y, Li M, Zhang C, et al. (2015) Identification of a 6-Cytokine Prognostic Signature in Patients with Primary Glioblastoma Harboring M2 Microglia/Macrophage Phenotype Relevance. PLoS ONE 10(5): e0126022. doi:10.1371/journal.pone.0126022

Academic Editor: Maria G Castro, University of Michigan School of Medicine, UNITED STATES

Received: August 22, 2014
Accepted: March 27, 2015
Published: May 15, 2015

Copyright: © 2015 Cai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are available from the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE48865.

Funding: This work was supported by the following sources of funding: 1. National High Technology Research and Development Program (863) (No. 2012AA02A508); 2. International Science and Technology Cooperation Program (No. 2012DFA30470); 3. National Natural Science Foundation of China (No. 91229121, No. 81201993); 4. Project of Ministry of Health P. R. China (No.

Abstract

Background
Glioblastomas (GBM) are comprised of a heterogeneous population of tumor cells, immune cells, and extracellular matrix. Interactions among these different cell types and pro-/anti-inflammatory cytokines may promote tumor development and progression.

Aims
The objective of this study was to develop a cytokine-related gene signature to improve outcome prediction for patients with primary GBM.

Methods
Here, we used Cox regression and risk-score analysis to develop a cytokine-related gene signature in primary GBMs from the whole transcriptome sequencing profile of the Chinese Glioma Genome Atlas (CGGA) database (n=105). We also examined differences in immune cell phenotype and immune factor expression between the high-risk and low-risk groups.

Results
Cytokine-related genes were ranked based on their ability to predict survival in the CGGA database. The six genes showing the strongest predictive value were CXCL10, IL17R, CCR2, IL17B, IL10RB, and CCL2. Patients with a high-risk score had poor overall survival and progression-free survival. Additionally, the high-risk group was characterized by
increased mRNA expression of M2 microglia/macrophage markers and elevated levels of IL10 and TGFβ1.

Conclusion
The six cytokine-related gene signature is sufficient to predict survival and to identify a subgroup of primary GBM exhibiting the M2 cell phenotype.

Introduction
Glioblastoma (GBM) is a common and aggressive form of diffuse glioma, associated with short survival and uniformly fatal outcome, irrespective of treatment [1, 2]. Histologically, malignant gliomas are characterized by hypercellularity, nuclear pleomorphism, microvascular proliferation, and pseudopalisading necrosis [3]. Reactive gliosis, microglial activation, and disrupted vasculature are all common characteristics of gliomas [4]. Other disease hallmarks include breakdown of the blood-brain barrier (BBB) and increases in both hypoxia and necrosis [5].

Patients with primary GBM have a median progression-free survival of just over half a year and a median overall survival of 15–18 months; only a minority of patients shows median survival beyond 2 years [6]. Given these clinical challenges and the immune heterogeneity of glioblastoma, immunotherapy is an appealing treatment for these tumors [7–9].

The tumor microenvironment (TME) consists of tumor cells, immune cells, inflammatory cells, endothelial cells, and extracellular matrix [10]. Macrophages, specifically referred to as tumor-associated macrophages (TAMs), are the most common cell type among tumor-infiltrating immune cells [11]. TAMs from human neoplasms express arginase1, IL10, and transforming growth factor beta (TGFβ); these cytokines reduce the anti-tumor activity of T cells and natural killer cells and modulate tumor proliferation, infiltration, and angiogenesis [1]. In this study, we aimed to identify a cytokine-related signature based on mRNA expression profiling, which could divide glioblastoma patients into high-risk and low-risk subgroups with distinct clinical prognosis. Immunologic gene signatures, indicative of activated microglia, were enriched in the high-risk subgroup. Previous studies of TAM populations in glioma tissues have shown that activated microglia/macrophages (especially M2) express high levels of CD68, CD163, CD204, and CD206 [5, 12–14]. Based on these findings, we used these specific markers to identify the activation of macrophage phenotypes in tumor samples. Consistently, we also observed that myeloid-derived suppressor cell (MDSC) subset markers CD11b, CD14, CD15, and CD33 were also elevated in the high-risk subgroup. TGFβ and IL10 are produced by a wide variety of cells including M2 macrophages, type 2 CD4 T-helper cells, myeloid-derived suppressor cells (MDSC), a subset of CD8 T cells, mast cells, and CD4+CD25+Foxp3+ Treg cells. Here, we find that both TGFβ and IL10 are implicated in malignancy of the high-risk subgroup tumors. These findings raise the possibility that treatment strategies targeting immunomodulatory cells infiltrating high-grade gliomas may be therapeutically useful.

Materials and Methods
Patients and Samples
Clinical information of 105 patients diagnosed with primary glioblastoma according to the 2007 World Health Organization (WHO) classification of tumors of the central nervous system [3] was obtained from the Chinese Glioma Genome Atlas (CGGA; http://www.cgga.org).
Tumor tissue samples were obtained by surgical resection. All patients (age range: 18–81 years) provided written informed consent. The study was approved by the institutional review boards of Capital Medical University, the Second Affiliated Hospital of Harbin Medical University and Beijing Institute for Brain Disorders Brain Tumor Center, and written informed consent was obtained from all patients. Survival data were collected by clinics during patient visits and/or phone interviews. Patients who underwent biopsy alone were not followed up at our center and were therefore excluded from the survival analysis. The Cancer Genome Atlas (TCGA) database (n = 518) was used as the validation set (http://cancergenome.nih.gov) [17].

**Whole transcriptome sequencing**

Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. A pestle and a QIAshredder (Qiagen) were used to disrupt and homogenize frozen tissue. RNA integrity was assessed using the 2100 Bioanalyzer (Agilent Technologies), and only high quality samples with an RNA Integrity Number (RIN) greater than or equal to 7.0 were used to construct the sequencing library. The subsequent steps included end repair, adapter ligation, size selection, and polymerase chain reaction enrichment. DNA fragment lengths were measured using a 2100 Bioanalyzer, with median insert sizes of 200 nucleotides. The libraries were sequenced on the Illumina HiSeq 2000 platform using the 101-bp paired-end sequencing strategy. Short sequence reads were aligned to the human reference genome (Hg 19 Refseq) using the Burrows-Wheeler Aligner (BWA, Version 0.6.2-r126) [18].

**Molecular analyses**

**Isocitrate dehydrogenase (IDH) mutations.** Genomic DNA was extracted from frozen tissues with a QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s protocol. DNA concentration and quality were measured using a Nano-Drop ND-1000 spectrophotometer (NanoDrop Technologies, Houston, TX). Pyrosequencing of IDH1/2 mutations was supported by Gene-tech (Shanghai, China) and performed on a Pyro-Mark Q96 ID System (Qiagen, Valencia, Calif). The following primers were used for PCR amplification: IDH1 5’-GCTTTGAGTGGATGGTAAAAAC-3’ and 5’-Biotin-TTGCCCAACATGACTTACTTGGATC-3’; and IDH2 5’-ATCCTTGGGGGGACTGTCTT-3’ and 5’-Biotin-CTCTCCACCCCTGGCCTACC-3’. The primer sequences used for pyrosequencing are 5’-TGGATGGGTAAAAACCCTGAAGT-3’ for IDH1 and 5’-AGCCCCATCACCATTG-3’ for IDH2 [19, 20].

**O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation.** MGMT promoter methylation status was assessed as previously reported [21]. Bisulfite modification of DNA was performed using the EpiTect Kit (Qiagen). Two primers were used to amplify the MGMT promoter region: 5’-GTTTYGGATAGTGGATGGATA-3’ and reverse: 5’-biotin-ACC CAAACACTCACCACAAAATC-3’. The PCR analysis was performed in duplicate in 40 μl reaction volume containing 0.5 μl of 10 μM each primer, 4μl 10× buffer, 3.2μl of 2.5 μM dNTPs, 2.5 U hotstart Taq (Takara, Madison, WI), and 2 μl of 10 μM bisulfite-treated DNA. The PCR conditions were as follows: 95°C–3 min; 40 cycles of 95°C–15 s, 52°C–30 s, 72°C–30 s; 72°C–5 min (ABI PCR system 9700). DNA was purified from the total PCR product using QIAamp DNA Mini Kit (Qiagen) and then subjected to pyrosequencing (PyroMark Q96 ID System (Qiagen)) using the primer 5’-GGATATGTGGGGATATG-3’ in accordance to the manufacturer’s instructions. The methylation values obtained were averaged across the seven CpG loci tested within the MGMT promoter. The GBM samples were considered MGMT promoter methylated with an average methylation of >10%.
**Statistical Analysis**

RNA sequencing data was downloaded from the CGGA dataset. Gene expression was calculated using the RPKM method (reads per kilobase transcriptome per million reads) [22, 23]. The RPKM method eliminates the influence of varying gene lengths and sequencing discrepancies from the calculation of gene expression. Therefore, the calculated gene expression can be directly used to compare the differences in gene expression among samples [24].

To integrate cytokine-related gene sets, 821 cytokine-related genes were first extracted from canonical biological pathways in the Molecular Signatures Database v4.0 (MSigDB) (http://www.broad.mit.edu/gsea/msigdb/) [25, 26] and then combined with 137 cytokine-related genes from three publications in *Journal of Allergy and Clinical Immunology* [27–29]. After removing overlapping genes between the two gene sources, the cytokine-related gene set contained a total of 593 genes. The prognostic value of these genes in patient survival was calculated by the Kaplan—Meier method with the two-sided log-rank test by two packages (survival and KMsurv) of R. The permuted $P$-value for each gene was corrected by multiple comparison correction using the Benjamini—Hochberg false discovery rate (FDR). The genes with corrected permutation $P$-values < 0.01 were selected as candidate genes. In the end, six genes remained.

To evaluate the prognostic effectiveness of the six genes, a risk-score formula for predicting survival was developed based on a linear combination of the mRNA expression level (expr) weighted by the regression coefficient derived from the univariate Cox regression analysis ($\beta$) [30, 31]. The risk score for each patient was calculated as follows:

$$\text{Risk score} = \text{expr}_{\text{gene1}} \times \beta_{\text{gene1}} + \text{expr}_{\text{gene2}} \times \beta_{\text{gene2}} + \cdots + \text{expr}_{\text{genen}} \times \beta_{\text{genen}}$$

We next divided patients in the training dataset into high-risk and low-risk groups using the median mRNA signature risk score as the cutoff point. Patients with higher risk scores are expected to have poor survival. The same $\beta$ was applied to the validation cohort.

Overall survival (OS) was defined as the period from the first operation to death or last follow-up. The progression-free survival (PFS) was defined as the period from the first operation to the time of tumor recurrence or evidence of progression based on magnetic resonance imaging (MRI). The differences in OS and PFS between high-risk patients and low-risk patients were estimated using the Kaplan—Meier method and 2-sided log-rank test in GraphPad Prism Version 6.01. Cox proportional hazards regression analyses were performed to assess the independent contribution of the mRNA signature and clinicopathologic variables to survival prediction.

GSEA was performed using Gene Set Enrichment Analysis v2 software downloaded from the Broad Institute (www.broadinstitute.org/gsea). The mRNA expression profile of GBM samples from the CGGA dataset was analyzed by GSEA [25, 26]. For GSEA, risk score was treated as a binary variable divided into low or high risk by a criterion of whether the score was greater than the median value. To determine detailed immunologic functional gene sets for GSEA, we used the immunologic signature gene sets from MSigDB [26]. All other parameters were set based on their default values.

Significant difference in the comparison of two experimental groups was determined by $t$ test. Excel was used for correlation analysis. Principal component analysis (PCA) was conducted to assess patterns in gene expression, and PCA was conducted with the R programming language (http://cran.r-project.org). STRING, a database of protein-protein interactions, was also used. STRING takes a list of gene products and returns a diagram of known and potential interactions [32]. Chi-Square test and Fisher’s exact test were used to compare the frequencies between groups in SPSS version 13.0 software for Windows (SPSS). All differences were considered statistically significant at the level of $p<0.05$. 
Results

Prediction of survival based on six cytokine-related genes signature in the CGGA database (the training cohort)

In 105 CGGA primary GBM samples, we used Cox regression to analyze each of 593 cytokine-related genes in the training set and identified six genes (CCL2, CCR2, CXCL10, IL10RB, IL17B, and IL17R) that were significantly associated with OS (S1 Table, \( P < 0.01 \)). We then performed the risk score method to construct a model for the prediction of survival based on these six genes [30, 31]. We calculated the signature risk score for each of the 105 patients in the training set and divided them into a high-risk group (\( n = 52 \)) and a low-risk group (\( n = 53 \)); the median risk score was used as the cutoff point. Table 1 shows the clinical characteristics of the patients in each of the two risk groups. The rates of overall survival at one year in the low-risk and high-risk groups were 59% and 34%, respectively; the two-year survival rates were 40% and 11%, respectively. The median survival time in the low-risk group was 514 days, and that in the high-risk group was 295 days (Fig 1A, \( P < 0.001 \)). The high-risk score group also had shorter progression-free survival than the group with low-risk score (Fig 1B, \( P < 0.01 \)).

Clinical characteristics (age, gender, pre-operative Karnofsky Performance Scale (KPS) score, and treatment) and molecular information (IDH mutation and MGMT methylation status) were obtained from the CGGA dataset and are shown in Table 1.

Confirmation of the signature for survival prediction in the TCGA database (the validation cohort)

To validate the prognostic value of the 6-cytokine signature, we applied the risk score formulas from the CGGA dataset to patients from the TCGA dataset and then ranked the patients with

---

Table 1. Clinicopathological characteristics of patients with primary glioblastoma in the CGGA dataset (n = 105).

| Variable                  | total | low risk score (n = 53) | high risk score (n = 52) | p value |
|---------------------------|-------|------------------------|--------------------------|---------|
| Age at diagnosis          |       |                        |                          |         |
| <45                       | 38    | 22                     | 16                       | >0.05   |
| ≥45                       | 67    | 31                     | 36                       |         |
| Gender                    |       |                        |                          |         |
| Male                      | 66    | 32                     | 34                       | >0.05   |
| Female                    | 39    | 21                     | 18                       |         |
| Preoperative KPS score    |       |                        |                          |         |
| <80                       | 55    | 25                     | 30                       | >0.05   |
| ≥80                       | 50    | 28                     | 22                       |         |
| NA                        | 0     | 0                      | 0                        |         |
| IDH1/2 Status             |       |                        |                          |         |
| MUT                       | 14    | 11                     | 3                        | <0.05   |
| WT                        | 80    | 35                     | 45                       |         |
| NA                        | 11    | 7                      | 4                        |         |
| MGMT promoter methylation |       |                        |                          |         |
| Methylation               | 27    | 18                     | 9                        | <0.05   |
| Unmethylation             | 48    | 17                     | 31                       |         |
| NA                        | 30    | 18                     | 12                       |         |
| Extent of surgery         |       |                        |                          |         |
| Total                     | 46    | 21                     | 25                       | >0.05   |
| Subtotal                  | 52    | 27                     | 25                       |         |
| NA                        | 7     | 5                      | 2                        |         |
| Radiotherapy              |       |                        |                          |         |
| Yes                       | 70    | 39                     | 31                       | >0.05   |
| No                        | 29    | 13                     | 16                       |         |
| NA                        | 6     | 1                      | 5                        |         |
| Chemotherapy              |       |                        |                          |         |
| Yes                       | 62    | 35                     | 27                       | >0.05   |
| No                        | 36    | 16                     | 20                       |         |
| NA                        | 7     | 2                      | 5                        |         |

doi:10.1371/journal.pone.0126022.t001
Fig 1. Development of the prognostic model. Kaplan—Meier curves for overall and progression-free survivals in the two groups (low risk and high risk) as defined by a prediction model based on the weighted expression of six genes (CCL2, CCR2, CXCL10, IL10RB, IL17B, and IL17R) (A, B). This Kaplan-Meier assessment of OS and PFS in patients with glioblastoma illustrates a risk score analysis using this signature in the TCGA cohort (C, D). The risk score has prognostic value of survival in the radiotherapy plus temozolomide group from both the CGGA and TCGA datasets (E, F, G, H).

doi:10.1371/journal.pone.0126022.g001
known risk scores in each respective situation. These patients were also divided into low- and high-risk groups, using the median risk score as a cut-off. The prognostic value of this signature was validated in the TCGA dataset (Fig 1C and 1D).

In patients treated with radiotherapy plus temozolomide—the standard treatment for primary GBM, the risk score predicted overall survival and progression-free survival in both datasets. Patients with a high-risk score had poor survival (Fig 1E and 1F, OS, \(P < 0.05\), 484 days vs. 970 days; PFS, \(P < 0.01\), 292 days vs. 208 days; Fig 1G and 1H, OS, \(P < 0.01\), 458 days vs. 611 days; PFS, \(P < 0.001\), 233 days vs. 333 days).

The distribution of patient risk scores, OS, and mRNA expression in GBM for both the training set and the validation set is provided in Fig 2A and 2B. Patients with high-risk scores expressed high levels of these six genes. Principal component analysis (PCA) shows a good separation between the high-risk group and the low-risk group in the primary GBM specimens according to the six cytokine signature (Fig 2C).

The 6-cytokine signature is an independent prognostic factor in primary GBM

We conducted univariate Cox regression analysis using clinical and genetic variables for the CGGA cohort (Table 2) and observed that the signature (risk score), radiotherapy, chemotherapy, pre-operative KPS score, and MGMT promoter methylation status were statistically associated with OS. We also found that risk score, chemotherapy, pre-operative KPS score, and MGMT promoter methylation status were associated with PFS. Multivariate Cox regression analysis indicated that the signature was an independent prognostic factor in the CGGA cohort (Table 2 OS: HR, 2.352; 95% CI, 1.256–4.403; \(P < 0.01\); PFS: HR, 1.78; 95% CI, 1.004–3.157; \(P < 0.05\)).

The high-risk score group from the 6-cytokine signature is associated with the M2 microglia/macrophage phenotype and exhibits increased expression of IL10 and TGF\(\beta\)1

To better understand the relationship between immunology and inflammation, we conducted gene expression analysis between the low-risk group and the high-risk group in the CGGA samples. Gene set enrichment analysis (GSEA) [26] revealed that the subgroup with high risk score had increased expression of activated microglia-associated genes (Fig 3A, 3B and 3C, NES = 1.76, \(P < 0.05\); B, NES = 2.31, \(P < 0.001\); C, NES = 2.27, \(P < 0.001\)). Using the mRNA sequencing gene expression profile, we observed that the M2 microglia/macrophage markers (CD68, CD163, CD204, CD206) [11–13] were significantly up-regulated in the high-risk subgroup compared to the low-risk subgroup (Fig 3D, \(P < 0.001\), \(P < 0.001\), \(P < 0.001\), \(P < 0.001\), respectively). Likewise, MDSC-specific transcripts (CD11b, CD14, CD15, CD33) [33] were found at elevated levels in the high-risk subgroup (Fig 3E, \(P < 0.001\), \(P < 0.001\), \(P < 0.001\), \(P < 0.001\), respectively). M2 markers, CD163 and CD204, and MDSC markers, CD11b, CD14, CD15, and CD 33, showed a similar pattern of increased expression in the high-risk subgroup of the TCGA dataset (S1 Fig; CD68 and CD206 were not included in the TCGA dataset.).

Compared to the low-risk group, IL10 and TGF\(\beta\)1 mRNA were significantly elevated in the high-risk score group from the CGGA dataset and the TCGA dataset (Fig 3F, S1G and S1H Fig). However, the M1 markers, iNOS and IL12, showed no significant difference between groups (Fig 3G, S1I and S1J Fig).

Using a more comprehensive panel of genes, we probed for associations between cell phenotype and immunomodulatory factors in the mRNA expression profile; results are displayed as a heat map (Fig 4A). The extent of Spearman correlation between the expression levels of the
different genes was statistically significant. There was a strong association between the expression of M2 macrophage markers (CD68, CD163, CD204, and CD206) and MDSC markers (CD11b, CD14, CD15, and CD33). Additionally, expression of CCL2, CCR2, IL10RB, and IL17R positively correlated with the M2 macrophage markers and MDSC markers. Fig 4A also shows that mRNA expression of monocyte markers positively correlates with the expression of IL10 and TGFβ1. In contrast, iNOS and IL12 negatively correlate with the M2 cell marker.
CD163 and the MDSC marker CD33. In addition, STRING was used to visualize the gene list, containing cell markers and immunoregulatory factors; it was also used to show potential gene product interactions (Fig 4B).

PCA was conducted to determine whether or not there may be latent associations common to the genes encoding M2 (CD11b, CD68, CD163, CD204, CD206) and MDSC (CD15, CD14, CD33) phenotypic markers. The six cytokine-related genes, IL10, and TGF\(\beta\)1, classical immunosuppressors, were also examined. The scores for individual samples (symbols) and the amount by which the expression of each gene “loads” on, or correlates with, the components (represented by the direction and length of the loading plot vectors) are shown in Fig 4C. The expression of genes that are near each other in the vector plots, for example, CD68, CD33, IL-17R, and TGF\(\beta\)1, is expected to be associated. Moreover, there is a geometric link between the arrows and symbols indicating that higher levels of cell phenotype markers and immunoregulatory genes were significant in characterizing primary GBM samples (Fig 4C).

Consistent with previous work [34], we also observed that mesenchymal glioblastomas were enriched in the high-risk subgroups, supporting the report that immune genes exhibited differential expression in glioblastoma subtypes, and immunosuppression dominated in mesenchymal glioblastomas (S2 Table; CGGA: P<0.0001; TCGA: P<0.0001).

### Discussion

In our present work, mRNA expression profile of 105 primary GBM samples was examined by whole transcriptome sequencing, because RNA-seq can add benefits for gene expression analysis such as quantitation of transcripts, improved dynamic range, and additional capabilities for detecting expressed single nucleotide variants (SNVs), translocations, and transcript isoform switches compared with microarray and immunochemistry [15, 35, 36]. We identified a six

| Variable                          | HR | 95% CI          | p value | HR | 95% CI          | p value |
|----------------------------------|----|-----------------|---------|----|-----------------|---------|
| **Overall Survival**             |    |                 |         |    |                 |         |
| Age at diagnosis                 | 1.038 | 0.644–1.672   | >0.05   |    |                 |         |
| Gender                          | 0.854 | 0.526–1.388    | >0.05   |    |                 |         |
| Preoperative KPS score           | 4.869 | 2.886–8.216    | <0.001  | 4.724 | 2.524–8.840    | <0.001  |
| Risk score                       | 2.323 | 1.426–3.785    | 0.001   | 2.352 | 1.256–4.403    | <0.01   |
| Chemotherapy                     | 2.23 | 1.373–3.622    | 0.001   | 1.923 | 0.998–3.705    | 0.051   |
| Radiotherapy                     | 1.914 | 1.146–3.194    | <0.05   | 0.887 | 0.449–1.753    | >0.05   |
| MGMT Methy vs. Unmethy           | 2.088 | 1.175–3.710    | <0.05   | 1.48  | 0.765–2.863    | >0.05   |
| IDH1/2 Mutation status           | 1.595 | 0.777–3.272    | >0.05   |    |                 |         |
| Extent of surgery                | 1.356 | 0.837–2.197    | >0.05   |    |                 |         |
| **Progression-free Survival**    |    |                 |         |    |                 |         |
| Age at diagnosis                 | 0.896 | 0.567–1.418    | >0.05   |    |                 |         |
| Gender                          | 0.805 | 0.501–1.291    | >0.05   |    |                 |         |
| Preoperative KPS score           | 4.514 | 2.722–7.487    | <0.001  | 3.926 | 2.173–7.094    | <0.001  |
| Risk score                       | 2.019 | 1.259–3.239    | <0.01   | 1.78  | 1.004–3.157    | <0.05   |
| MGMT Methy vs. Unmethy           | 1.931 | 1.104–3.379    | <0.05   | 1.415 | 0.762–2.629    | >0.05   |
| Chemotherapy                     | 1.974 | 1.229–3.169    | <0.01   | 1.404 | 0.784–2.514    | >0.05   |
| Radiotherapy                     | 1.422 | 0.857–2.362    | >0.05   |    |                 |         |
| IDH1/2 Mutation status           | 1.313 | 0.667–2.587    | >0.05   |    |                 |         |
| Extent of surgery                | 1.225 | 0.771–1.945    | >0.05   |    |                 |         |

DOI:10.1371/journal.pone.0126022.t002
gene cytokine-related signature (CCL2, CCR2, CXCL10, IL10RB, IL17B, and IL17R) capable of dividing glioblastoma patients into a low risk score group with favorable survival and a high risk score group with poor survival. CCL2 (MCP1) is a cognate ligand for chemokine receptor CCR2, which is expressed by monocytes in peripheral blood and plays multiple roles in cancer, including chemoattraction of circulating CCR2-positive monocytes/macrophages to the tumor vicinity [37, 38]. IL17 is a pro-inflammatory cytokine, which induces production of other pro-inflammatory cytokines, chemokines, and prostaglandins. IL17 includes six families (IL17A through F) expressed by lots of innate and adaptive immune cells, including epithelial cells, invariant natural killer T cells, natural killer cells, lymphoid-tissue inducer-like cells, neutrophils, T cells and so on [39]. In non-small-cell lung cancer patients, higher levels of IL17 within the tumor correlates with higher blood vessel density and shorter survival [40]. We have shown that expression of both IL17B and IL17 receptor are associated with survival of patients with primary GBM. Previous work has also demonstrated that endogenous CXCL10 could inhibit glioma development and promote tumor infiltration of CD8+ T cells in transgenic mice; additionally, myeloid-derived suppressor cells (MDSCs) produce CXCL10, indicating that they are pleiotropic [38, 41]. We found that GBM patients harboring high mRNA expression of
Fig 4. Expression patterns of cell markers and immunomodulatory genes, and Model of M2 microglia/macrophage production in GBM. (A) Heat map representation of statistically significant differentially expressed genes (P<0.05). Spearman correlation was performed between the expression levels of the indicated gene pairs in the cohort (Spearman coefficients are shown as colors corresponding to the scale bar). Gray represents gene combinations without significant correlation. (B) Protein interaction subnetwork based on protein-coding genes and their interacting partners. Nodes represent protein coding genes; links represent physical interactions. Nodes in color indicate enriched biological functions of the proteins. A red line is indicative of fusion; green line—neighborhood evidence; blue line—co-occurrence evidence; purple line—experimental evidence; yellow line—text mining evidence; light blue...
CXCL10 had shorter overall survival in both CGGA and TCGA datasets. More work needs to be done to better understand the role of CXCL10 in glioma tumorigenesis.

We identified that the high-risk score group from the 6-cytokine signature was associated with the M2 microglia/macrophage phenotype and exhibited increased expression of IL10 and TGFβ1. These data suggested that malignant glioma cells might induce TAMs to create a favorable microenvironment for glioma progression. Microglia are abundant in the CNS and comprise approximately 5–10% (depending on the region) of all brain cells [42]. A hallmark of glioblastoma is the large number of immune cells (i.e. microglia/macrophages) that accumulate in the tumor mass [43, 44]. The number of TAMs (tumor associated microglia/macrophages) can be very high and constitute up to 30% of the tumor mass in GBM [5, 14]. Moreover, TAM number is typically higher in glioblastomas compared to grade II or III gliomas; it also closely associates with vascular density in tumors [12]. TAMs that populate gliomas can originate from either activated intrinsic parenchymal microglia or from macrophages freshly derived from bone marrow precursors in the blood [14, 45]. Peripheral blood-derived macrophages are largely restricted to the perivascular areas, meninx, and choroid plexus in the tumor-free brain; however, in GBM, these macrophages tend to assemble following the breakdown of the BBB [46]. Glioma-microglia/macrophage synergy drives a self-amplifying process in the tumor microenvironment. Glioma cells and microglial cells have a symbiotic relationship that becomes highly skewed in favor of the glioma. Glioma cells produce chemotactic factors, such as CCL2 and M-CSF, resulting in the recruitment of microglia and peripheral blood-derived macrophages. Glioma cells further promote the proliferation of microglia/macrophages. The immunosuppressive microenvironment created by molecules such as TGFβ and IL10 polarizes tumor-infiltrating microglia/macrophages toward the M2 phenotype. Lots of studies still delineated that TGFβ1 played a key role in affecting the malignant phenotype, including cell proliferation-promotion, migration and invasion-increasing, and apoptosis-inhibitor[47–52]. TGFβ1 increased glioma-initiating cells (GICs) self-renewal through the induction of LIF and the JAK-STAT pathway[53], and TGFβ inhibitors were emerging as compounds targeting GICs[54]. IL10 was associated with glioma progression. High grade gliomas expressed higher level of IL10 produced by glioma infiltrating macrophages (GIMs)[55]. IL10 was an important cytokine during glioma progression as a result that it promoted glioma invasion as well as an immunosuppressive environment[56]. In turn, M2 microglia/macrophages, influenced by the tumor itself, promote glioma growth, progression, invasion, and angiogenesis (Fig 4D) [14]. Tumor associated macrophages typically are shifted toward the M2 phenotype, tumor promoting, and immunosuppressive[57, 58]. miR-142-3p administration resulted in glioma growth inhibition by modulating M2 macrophages through the transforming growth factor beta signaling pathway[25]. Based on our result, targeting tumor-associated microglia/macrophages may be a novel, useful therapeutic approach for the high risk score group patients.

In conclusion, our signature reflects the proportion of M2 microglia/macrophages between the high-risk group and the low-risk group. The signature can be used to assess glioblastoma patient prognosis. It also provides new information regarding immunotherapy and the infiltration of immune cells into glioma tumors.
Supporting Information

S1 Fig. Confirmation of mRNA expression (cell phenotype and immunomodulatory genes) in the high and low subgroups in the TCGA dataset. CD163 and CD204 are significantly upregulated in the high-risk group (A, B; CD68 and CD206 were not included in the TCGA dataset). Expression of CD11b, CD14, CD15, and CD33 were increased in the high-risk group (C, D, E, F). TGFβ1 and IL10 are expressed at higher levels in the high-risk group (G, H). iNOS and IL12 are not significantly different between the low-risk and high-risk groups (I, J).

(SIF)

S1 Table. Six cytokines/receptors gene associated significantly with overall survival (OS).

(DOC)

S2 Table. Enrichment of mesenchymal glioblastomas in high risk group.

(DOC)

Acknowledgments

We thank Yuling Yang for tissue sample collection and clinical data retrieval.

Author Contributions

Conceived and designed the experiments: TJ CJ. Performed the experiments: JC WZ PY YW ML. Analyzed the data: CZ ZW HH YL. Contributed reagents/materials/analysis tools: QL JW BS XW. Wrote the paper: JC WZ.

References

1. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. The Journal of pathology. 2014; 232(2):165–77. doi:10.1002/path.4282 PMID: 24114756.
2. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005; 109(1):93–108. doi:10.1007/s00401-005-0991-y PMID: 15685439.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica. 2007; 114(2):97–109. doi:10.1007/s00401-007-0243-4. WOS:000248046800001. PMID:17618441
4. Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Bigner DD, et al. Glioblastoma multiforme: a review of therapeutic targets. Expert opinion on therapeutic targets. 2009; 13(6):701–18. doi:10.1517/14728220902942348 PMID: 19409033.
5. Glass R, Synowitz M. CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol. 2014. doi: 10.1007/s00401-014-1274-2 PMID: 24722970.
6. Chintot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. The New England journal of medicine. 2014; 370(8):709–22. doi: 10.1056/NEJMoai308345 PMID: 24552318.
7. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(15):5515–25. doi: 10.1158/1078-0432.CCR-05-0464 PMID: 16061868.
8. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001; 61(3):842–7. PMID: 11221866.
9. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(31):4722–9. doi: 10.1200/JCO.2010.28.6963 PMID: 20921459; PubMed Central PMCID: PMC3020702.
10. Frei K, Weller M. Cytokine networks in glioma Comments. Neurosurgical Review. 2011; 34(3):263–4. WOS:000291749100003.

11. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. The Journal of pathology. 2008; 216(1):15–24. Epub 2008/06/17. doi: 10.1002/path.2370 PMID: 18553315.

12. Nishie A, Ono M, Shono T, Fukushima J, Otsubo M, Onoue H, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999; 5(5):1107–13. PMID: 10353745.

13. Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(14):3776–86. doi: 10.1158/1078-0432.CCR-12-1940 PMID: 23741072.

14. Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. Neuro-Oncology. 2012; 14(8):958–78. doi: 10.1093/neuonc/nos116 PMID: 22573310

15. Cai J, Yang P, Zhang C, Zhang W, Liu Y, Bao Z, et al. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples. Oncotarget. 2014. PMID: 24810474.

16. Yan W, Zhang W, You G, Zhang JX, Han L, Bao ZS, et al. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro-Oncology. 2012; 14(12):1432–40. doi: 10.1093/neuonc/nos263 PMID: 23741072.

17. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salmara SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2):462–77. doi: 10.1016/j.cell.2013.09.034 PMID: 24120142; PubMed Central PMCID: PMC3910500.

18. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754–60. doi: 10.1093/bioinformatics/btp324 PMID: 19451168; PubMed Central PMCID: PMC2705234.

19. Yan W, Zhang W, You G, Bao ZS, Wang YZ, Liu YW, et al. Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China. PLoS One. 2012; 7(1):e30339. Epub 2012/02/01. doi: 10.1371/journal.pone.0030339 PMID: 22291938; PubMed Central PMCID: PMCPMC3264567.

20. Audic S, Claverie JM. The significance of digital gene expression profiles. Genome research. 1997; 7(10):986–95. PMID: 9331369.

21. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34(3):267–73. doi: 10.1038/ng1180 PMID: 12808457.

22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545–50. doi: 10.1073/pnas.0506580102 PMID: 16199517; PubMed Central PMCID: PMC1239896.

23. Chaplin DD. 1. Overview of the immune response. Journal of Allergy and Clinical Immunology. 2003; 111(2):S442–S59. doi: 10.1067/mai.2003.125 PMID: 12592292

24. Borish LC, Steinke JW. 2. Cytokines and chemokines. Journal of Allergy and Clinical Immunology. 2003; 111(2):S460–S75. doi: 10.1067/mai.2003.108 PMID: 12592293

25. Steinke JW, Borish L. 3. Cytokines and chemokines. The Journal of allergy and clinical immunology. 2006; 117(2 Suppl Mini-Primer):S441–5. doi: 10.1016/j.jaci.2005.07.001 PMID: 16455343.
30. Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, et al. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer. 2013; 119(4):814–24. doi: 10.1002/cncr.27826 PMID: 22990979.

31. Lossos IS, Czerwinski DK, Alizadeh AA, Wechsler MA, Tilshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. New England Journal of Medicine. 2004; 350(18):1828–37. doi: 10.1056/NEJMoa032520. WOS:000221083000006. PMID: 15115829.

32. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic acids research. 2013; 41(Database issue):D808–15. doi: 10.1093/nar/gks1094 PMID: 23203871; PubMed Central PMCID: PMC3531103.

33. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011; 13(6):591–9. doi: 10.1039/neur0nc/nor042 PMID: 21636707; PubMed Central PMCID: PMC3107102.

34. Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, et al. Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas. Cancer immunology research. 2013; 1(12). doi: 10.1158/2326-6066.CIR-13-0028 PMID: 24409449; PubMed Central PMCID: PMC3881271.

35. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nature Reviews Genetics. 2011; 12(2):87–98. doi: 10.1038/nrg2934. WOS:000286319600010. PMID: 21191423.

36. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nature Reviews Genetics. 2009; 10(1):57–63. doi: 10.1038/nrg2484. WOS:000261866500012. PMID: 19015660.

37. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer metastasis reviews. 2006; 25(3):315–22. doi: 10.1007/s10555-006-9001-7 PMID: 16673622.

38. Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007; 252(1):86–92. doi: 10.1016/j.canlet.2006.12.012 PMID: 17257744.

39. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, et al. Th17 cells in cancer: help or hindrance? Carcinogenesis. 2011; 32(5):643–9. doi: 10.1093/carcin/bgr019 PMID: 21304053; PubMed Central PMCID: PMC3086699.

40. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung cancer. 2010; 69(3):348–54. doi: 10.1016/j.lungcan.2009.11.013 PMID: 2022135.

41. Uremura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. Journal of leukocyte biology. 2008; 83(5):1136–44. doi: 10.1189/jlb.0907611 PMID: 18285406.

42. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of Microglia. Physiological Reviews. 2011; 91(2):461–88. doi: 10.1152/physrev.00011.2010. WOS:000290017800003. PMID: 21527731.

43. Penfield W. Microglia and the Process of Phagocytosis in Glia. The American journal of pathology. 1925; 1(1):77–90. PMID: 19969634; PubMed Central PMCID: PMC1931672.

44. Badie B, Schartner JM. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery. 2000; 46(4):957–61; discussion 61–2. PMID: 10764271.

45. Benaroch EE. Microglia Multiple roles in surveillance, circuit shaping, and response to injury. Neurology. 2013; 81(12):1079–88. WOS:000330767900014. doi: 10.1212/WNL.0b013e3182a4a577 PMID: 23946308.

46. Rolle CE, Sengupta S, Lesniak MS. Mechanisms of immune evasion by gliomas. Adv Exp Med Biol. 2012; 746:53–76. doi: 10.1007/978-1-4614-3146-6_5 PMID: 22639159.

47. Merzak A, McCrea S, Koocheckpour S, Pilkington GJ. Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. British journal of cancer. 1994; 70(2):199–203. PMID: 8054266; PubMed Central PMCID: PMC2033507.

48. Wick W, Platten M, Weller M. Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol. 2001; 53(2):177–85. PMID: 11716069.

49. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. International journal of cancer. 2000; 89(3):251–8. PMID: 10861501.

50. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. International journal of cancer. 1995; 62(4):386–92. PMID: 7635563.
51. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007; 11(2):147–60. doi: 10.1016/j.ccr.2006.11.023 PMID: 17292826.

52. Held-Feindt J, Lütjohann B, Ungefroren H, Mehdorn HM, Mentlein R. Interaction of transforming growth factor-beta (TGF-beta) and epidermal growth factor (EGF) in human glioma cells. J Neurooncol. 2003; 63(2):117–27. PMID: 12825816.

53. Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009; 15(4):315–27. Epub 2009/04/07. doi: 10.1016/j.ccr.2009.02.011 PMID: 19345330.

54. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, et al. TGF-beta Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell. 2010; 18(6):655–68. Epub 2010/12/16. doi: 10.1016/j.ccr.2010.10.023 PMID: 21156287.

55. Wagner S, Czub S, Greif M, Vince GH, Suss N, Kerkau S, et al. Microglial/macrophage expression of interleukin 10 in human glioblastomas. International journal of cancer Journal international du cancer. 1999; 82(1):12–6. PMID: 10360813.

56. Huettner C, Czub S, Kerkau S, Roggendorf W, Tonn JC. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer research. 1997; 17(5A):3217–24. PMID: 9413151.

57. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Human immunology. 2009; 70(5):325–30. doi: 10.1016/j.humimm.2009.02.008 PMID: 19236898.

58. Pollard JW. Trophic macrophages in development and disease. Nature reviews Immunology. 2009; 9(4):259–70. doi: 10.1038/nri2526 PMID: 19282852; PubMed Central PMCID: PMC3648866.